Clinical trials: Persistent Advanced Cervical Carcinoma
Locally Advanced Cervical Cancer, Prognostic Biomarker
Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors
Cervical cancer is strongly associated with HPV infection, yet current post-treatment follow-up relies on cytology and imaging, which have limited accuracy, particularly after radiotherapy.
- Trial name
- ANIHTA (NCT07600515)
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy
- Trial name
- NCT05310383
- Testing
- Tislelizumab plus radiotherapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Lei Li
Cervical Cancer
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00691301
- Testing
- cisplatin, pemetrexed disodium
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
Study of Cisplatin in Cervical Cancer Stage IVB
This is a single arm, open-label study in women from China who have Advanced (stage IVB) Recurrent or Persistent cervical cancer to ⑴assess the response rate (i.e., CR + PR) of Cisplatin combined with Topotecan in treatment of…
- Trial name
- NCT00826891
- Testing
- Cisplatin Combined With Topotecan
- Volunteers
- 40 people
- Sponsor
- Chinese Anti-Cancer Association
Stage IVB Cervical Cancer, Recurrent Cervical Cancer
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04974944
- Testing
- Camrelizumab, Apatinib, Paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Cervical Cancer
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
The purpose of this study is to determine the efficacy and safety the combination of TRANSKRIP ® vs placebo plus Carboplatin/Paclitaxel as first line treatment in patients with recurrent-persistent cervical cancer.
- Trial name
- NCT02446652
- Testing
- Hydralazine/Magnesium, Carboplatin, Paclitaxel
- Where
- Mexico
- Sponsor
- National Institute of Cancerología
Cervical Cancer
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
This study was an open, single-arm, enriched, multicenter Phase II study.
- Trial name
- NCT06226350
- Testing
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or…
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody
- Trial name
- NCT04188860
- Testing
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Lei Li
Cervical Cancer
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101192
- Testing
- cetuximab, cisplatin
- Where
- 18 sites in United States
- Volunteers
- 76 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276796
- Testing
- cisplatin, paclitaxel, topotecan hydrochloride
- Volunteers
- 66 people
- Sponsor
- Gynecologic Oncology Group
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
- Trial name
- NCT00430781
- Testing
- pazopanib (GW786034), lapatinib (GW572016)
- Where
- 63 sites in United States, Argentina and 11 more
- Volunteers
- 228 people
- Sponsor
- GlaxoSmithKline
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors
- Trial name
- NCT05290935
- Testing
- Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Lei Li
Cervical Cancer, Cervix Cancer
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Cervical Cancer, Cervix Cancer, Cervix Neoplasm
- Trial name
- NCT04651127
- Testing
- Toripalimab + Chidamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical…
- Conditions
- Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy, Recurrent Cervical Carcinoma
- Trial name
- NCT05310305
- Testing
- Radiotherapy for targeted lesions and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Cervical Cancer
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced…
- Trial name
- NCT00016926
- Testing
- capecitabine
- Where
- 10 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Cervix Cancer
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of topotecan when given weekly with cisplatin in patients with persistent, recurrent, or advanced stage cervical cancer.
- Trial name
- NCT00322920
- Testing
- Topotecan, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Cervical Cancer
Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138151
- Testing
- recombinant interferon alpha-2b, isotretinoin, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Targeted Therapy, Chemotherapy
Donafenib for Recurrent Cervical Cancer
This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.
- Conditions
- Targeted Therapy, Chemotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT05310331
- Testing
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Cervical Cancer, Vaginal Cancer
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced…
- Trial name
- NCT00002562
- Testing
- paclitaxel
- Where
- 50 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gynecologic Oncology Group